Role of Chemokines and Chemokine Receptors in Diseases of Ageing

  • Erminia Mariani
  • Adriana Rita Mariani
  • Andrea Facchini
Part of the Medical Intelligence Unit book series (MIUN)


Chemokines play an important role in orchestrating leukocyte recruitment and activation during inflammation. Given the ubiquity of chemokines involved in inflammatory tissue destruction, it is not surprising that they contribute to numerous human pathologies. Epidemiological studies have suggested that chronic low-grade inflammation is related to several diseases of ageing with an inflammatory pathogenesis (such as atherosclerosis, type 2 diabetes, osteoarthritis and Alzheimer’s disease) and to increased mortality risk. In this chapter, we will briefly review the properties of chemokines and their receptors and highlight the roles of these chemoattractants in the above selected diseases of ageing.


Diabetic Nephropathy Mild Cognitive Impairment Clin Invest Chemokine Receptor Senile Plaque 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Licastro F, Candore G, Lio D et al. Innate immunity and inflammation in ageing: a key understanding age-related diseases. Immun Ageing 2005; 2:8.PubMedGoogle Scholar
  2. 2.
    Sarkar D, Fisher PB. Molecular mechanisms of ageing-associated inflammation. Cancer Lett 2006: 236:13–23.PubMedGoogle Scholar
  3. 3.
    Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338:436–445.PubMedGoogle Scholar
  4. 4.
    Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nature Immunol 2001; 2:123–128.Google Scholar
  5. 5.
    Ono SJ, Nakamura T, Miyazaki D et al. Chemokines: role in leukocyte development, trafficking and effector function: J Allergy Clin Immunol 2003; 111:1185–1199.PubMedGoogle Scholar
  6. 6.
    Moser B, Wolf M, Walz et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25:75–84.PubMedGoogle Scholar
  7. 7.
    Moser B, Willimann. Chemokines: role in inflammtion and immune surveillance. Ann Rheum Dis 2004; 63 suppl II:ii84–ii89.PubMedGoogle Scholar
  8. 8.
    Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610–621.PubMedGoogle Scholar
  9. 9.
    Pawelec G, Barnett Y, Forsey R et al. T-cells and ageing, 2002. Front Biosci 2002; 7:d1056–d1183.PubMedGoogle Scholar
  10. 10.
    Inadera H, Egashira K, Takemoto M et al. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J Interferon Cytokine Res 1999; 19:1179–1182.PubMedGoogle Scholar
  11. 11.
    Gerli R, Monti D, Bistoni O et al. Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech Ageing Dev 2000; 12:37–46.Google Scholar
  12. 12.
    Antonelli A, Rotondi M, Fallahi P et al. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006; 34:32–38.PubMedGoogle Scholar
  13. 13.
    Wieczorowska-Tobis K, Niemir ZI, Podkowka R et al. Can an increased level of circulating IL-8 be a predictor of human longevity? Med Sci Monit 2006; 12:CR118–CR121.PubMedGoogle Scholar
  14. 14.
    Pulsatelli L, Meliconi R, Mazzetti I et al. Chemokine production by peripheral blood mononuclear cells in elderly subjects. Mech Ageing Dev 2000; 12:89–100.Google Scholar
  15. 15.
    Gabriel P, Cakman I, Rink L. Overproduction of monokines by leukocytes after stimulation with lipopolysaccaride in the elderly. Exp Gerontol 2002; 37:235–247.PubMedGoogle Scholar
  16. 16.
    Gerard C, Rollins BJ: Chemokines and disease. Nature Immunol 2001; 2:108–115.Google Scholar
  17. 17.
    Dong VM, McDermott DH, Abdi R. Chemokines and diseases. Eur J Dermatol 2003; 13:224–230.PubMedGoogle Scholar
  18. 18.
    Wick G, Jansen-Durr P, Berger P et al. Diseases of aging. Vaccine 2000; 18:1567–1583.PubMedGoogle Scholar
  19. 19.
    Rossi D, Zlotinick A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217–242.PubMedGoogle Scholar
  20. 20.
    Zlotnick A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121–127.Google Scholar
  21. 21.
    Homey B, Muller A, Zlotnick A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2:175–184.PubMedGoogle Scholar
  22. 22.
    Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250:91–104.PubMedGoogle Scholar
  23. 23.
    Murphy PM, Baggiolini M, Charo IF et al. International union of pharmacology. XII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52:145–176.PubMedGoogle Scholar
  24. 24.
    Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340:115–126.PubMedGoogle Scholar
  25. 25.
    Francisco G, Hernandez C Simò R. Serum markers of vascular inflammation in dyslipemia. Clin Chim Acta 2006; 369:1–16.PubMedGoogle Scholar
  26. 26.
    Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27–32.PubMedGoogle Scholar
  27. 27.
    Vaapatalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 2001; 7:1075–1085.Google Scholar
  28. 28.
    Gosling J, Slaymaker S, Gu L et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103:773–778.PubMedGoogle Scholar
  29. 29.
    Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2:275–281.PubMedGoogle Scholar
  30. 30.
    Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394:894–897.PubMedGoogle Scholar
  31. 31.
    Kuziel WA, Dawson TC, Quinones MK et al. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE Knockout mice. Atherosclerosis 2003; 167:25–32.PubMedGoogle Scholar
  32. 32.
    Nelken NA, Coughlin SR, Gordon D et al. Monocyte chemoattractant protein-1 in human atheroma plaques. J Clin Invest 1991; 88:1121–1127.PubMedGoogle Scholar
  33. 33.
    Yu X, Dluz S, Graves DT et al. Elevated expression of monocyte chemoattractant protein-1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992; 89:6953–6957.PubMedGoogle Scholar
  34. 34.
    Kowalski J, Okopien B, Madej A et al. Levels of sICAM-1, sVCAM-1 and MCP-1 in patients with hyperlipoproteinemia IIa and IIb. Int J Clin Pharmacol Ther 2001; 39:48–52.PubMedGoogle Scholar
  35. 35.
    Matsumori A, Furukawa Y, Hashimoto T et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997; 29:419–423.PubMedGoogle Scholar
  36. 36.
    Nishiyama K, Ogawa H, Yasue H et al. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndrome. Jpn Circ J 1998; 62:710–712.PubMedGoogle Scholar
  37. 37.
    Larsson PT, Hallertstam S, Rosfors S et al. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int Angiol 2005; 24:43–51.PubMedGoogle Scholar
  38. 38.
    Wang N, Tabas I, Winchester R et al. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996; 271:8837–8842.PubMedGoogle Scholar
  39. 39.
    Rothenbacher D, Muller-Scholze S, Herder C et al. Differential expression of chemokines, risk of stable coronary heart disease and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26:194–199.PubMedGoogle Scholar
  40. 40.
    Herder C, Baumert J, Thorand B et al. Chemokines and Incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol 2006; 26.Google Scholar
  41. 41.
    Szalai C, Duba J, Prohaszka Z et al. Involvement of polymorphism in the chemokine system in the susceptibility for coronary artery disease (CAD): coincidence of elevated Lp(a) and MCP-1-2518G/G genotype in CAD patients. Atherosclerosis 2001; 158:233–239.PubMedGoogle Scholar
  42. 42.
    Gonzalez P, Alvarez R, Batalla A et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2:191–195.PubMedGoogle Scholar
  43. 43.
    Molestina RE, Dean D, Miller RD et al. Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the amp 1 gene and biological activity in human endothelial cells. Infect Immun 1998; 66:1370–1376.PubMedGoogle Scholar
  44. 44.
    Streblow DN, Sodenberg-Naucler C, Vieira J et al. The human cytomegalovirus chemokine receptor U28 mediates vascular smooth muscle cell migration. Cell 1999; 99:511–520.PubMedGoogle Scholar
  45. 45.
    Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/-mice reveals a role for fraktalkine in atherogenesis, J Clin Invest 2003; 111:333–340.PubMedGoogle Scholar
  46. 46.
    Boisvert WA, Santiago R, Curtiss LK et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor deficient mice. J Clin Invest 1998; 101:353–363.PubMedGoogle Scholar
  47. 47.
    Combadiere C, Potteaux S, Gao JL et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double Knockout mice. Circulation 2003; 107:1009–1016.PubMedGoogle Scholar
  48. 48.
    McDermott DH, Halcox JP, Schenke WH et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89:401–407.PubMedGoogle Scholar
  49. 49.
    Moatti D, Faure S, Fumeron F et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97:1925–1928.PubMedGoogle Scholar
  50. 50.
    Horvath C, Welt FG, Nedelman M et al. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on the type of injury and leukocyte targeted. Circ Res 2002; 90:488–494PubMedGoogle Scholar
  51. 51.
    Damas JK, Waehre T, Yndestad A et al. SDF-1 alpha in unstable angina: potential anti-inflammatory and matrix stabilizing effects. Circulation 2002; 106:36–42.PubMedGoogle Scholar
  52. 52.
    Prentki M, Nolan CJ. Islet β cell failure in type 2 diabetes. J Clin Invest 2006; 116:1802–1812.PubMedGoogle Scholar
  53. 53.
    Festa A, Hanley AJ, Tracy RP et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003; 108:1822–1830.PubMedGoogle Scholar
  54. 54.
    Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J Clin Invest 2006; 116:1784–1792.PubMedGoogle Scholar
  55. 55.
    Friedman JM. The function of leptin in nutrition, weight and physiology. Nutr Rev 2002; 60:S1–S14.PubMedGoogle Scholar
  56. 56.
    Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Practice Res Clin Endocrinol Metab 2005; 19:547–566.Google Scholar
  57. 57.
    Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796–1808.PubMedGoogle Scholar
  58. 58.
    Ku H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821–1830.Google Scholar
  59. 59.
    Gerhardt CC, Romero IA, Cancello R et al. Chemokines control fat accumulation and leptin secretion by cyltured human adipocytes. Mol Cell Endocrinl 2001; 175:81–92.Google Scholar
  60. 60.
    Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein-1 in obesity and insulin resistance. Proc Nat Acad Sci USA 2003; 100:7265–7270.PubMedGoogle Scholar
  61. 61.
    Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects on high-fat feeding. J Clin Invest 2006; 116:115–124.PubMedGoogle Scholar
  62. 62.
    Takaishi M, Taniguchi T, Takahashi A et al. High glucose accelerate MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res commun 2003; 305:122–128.PubMedGoogle Scholar
  63. 63.
    Shanmigam N, Reddy MA, Guha M et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52:1256–1264.Google Scholar
  64. 64.
    He G, Bruun JM, Lihn AS et al. Stimulation of PAI-I and adipokines by glucose in human adipose tissue in vitro. Biochem Biophys Res Comm 2003; 310:878–883.PubMedGoogle Scholar
  65. 65.
    Straczkowski M, Kowalska I, Nilolajuk A et al. Plasma interleukin 8 concentration in obese subjects with impaired glucose tolerance. Cardiovasc Diabetol 2003; 2:5.PubMedGoogle Scholar
  66. 66.
    Zietz B, Buchler C, Herfarth H et al. Caucasion patients with type diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the −2518A/G promoter polymorphism. Diabetes Obes Metab 2005; 7:570–578.PubMedGoogle Scholar
  67. 67.
    Herder C, Baumert J, Thorand B et al. Chemokines as risk factor for type 2 diabetes: results from the MONICA/Kora Ausburg study, 1984–2002. Diabetologia 2006; 49:921–929.PubMedGoogle Scholar
  68. 68.
    Mine S, Okada Y, Tanikawa T et al. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Comm 2006; 344:780–785.PubMedGoogle Scholar
  69. 69.
    Chow F, Ozols DJ, Nikolic-Paterson RC et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65:1007–1012.Google Scholar
  70. 70.
    Wada T, Furuiki K, Sakai N et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58:1492–1499.PubMedGoogle Scholar
  71. 71.
    Mitamura Y, Takeuki S, Matsuda A et al. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 2001; 215:415–418.PubMedGoogle Scholar
  72. 72.
    Schlodorff D. Nelson PJ, Luckow J et al. Chemokine and renal disease. Kidney Int. 1997; 51: 610–621.Google Scholar
  73. 73.
    Mokubo A, Tanaka Y, Nakajiama K et al. Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients type 2 diabetes: a 10-year longitudinal study. Diabetes Res Clin Pract 2006; 73:89–94.PubMedGoogle Scholar
  74. 74.
    Schurman DJ, Smith RL. Osteoarthritis. Clin Orthop Rel Res 2004; 427S:S183–S189.Google Scholar
  75. 75.
    Yuan GH, Masuko-Hongo K, Sakata M et al. The role of C-C chemokines and their receptors in Osteoarthritis. Arthritis Rheum 2001; 44:1056–1070.PubMedGoogle Scholar
  76. 76.
    Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 1996; 25:254–272.PubMedGoogle Scholar
  77. 77.
    Shimmeri M, Masuda K, Kikuchi T et al. Production of cytokines by chondrocytes and its role in proteoglycan degradation. J Rheumatol Suppl 1991; 27: 89–91.Google Scholar
  78. 78.
    Borzì RM, Mazzetti I, Marcu K et al. Chemokines in cartilage degradation. Clin Orthop Rel Res 2004; 427S:S53–S61.Google Scholar
  79. 79.
    Smith MD, Triantafillou S, Parker A et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24:365–371.PubMedGoogle Scholar
  80. 80.
    Haywood L, McWilliams DF, Pearson CI et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003; 48:2173–2177.PubMedGoogle Scholar
  81. 81.
    Villinger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflammed synovial tissue and cultured synoviocytes. J Immunol 1992; 149:722–727.Google Scholar
  82. 82.
    Seitz M, Loetscher P, Dewald B et al. Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins and prostaglandin E by rheumatoid and osteoarthritic synoviocytes-regulation by IFN-gamma and IL-4. J Immunol 1994; 152:2060–2065.PubMedGoogle Scholar
  83. 83.
    Volin MV, Shah MR, Takuira M et al. RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol Immunopathol 1998; 89:44–53.PubMedGoogle Scholar
  84. 84.
    Merz D, Liu R, Johnson K et al. IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol 2003; 171:4406–4415.PubMedGoogle Scholar
  85. 85.
    Conti P, Reale M, Barbacane RC et al. Differential production of RANTES and MCP-1 in synovial fluid from the inflammed human knee. Immunol Lett 2002; 80:105–111.PubMedGoogle Scholar
  86. 86.
    Haringman JJ, Smeets TJM, Reinders-Blankert P et al. Chemokine and chemokine receptors expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis and reactive arthritis. Ann Rheum Dis 2006; 65:294–300.PubMedGoogle Scholar
  87. 87.
    Koch AE, Kunkel SL, Shah MR et al. Macrophage inflammatory protein −1 beta: a C-C chemokine in osteoarthritis. Clin Immunol Immunopathol 1995; 77:307–314.PubMedGoogle Scholar
  88. 88.
    Borzì RM, Mazzetti I, Macor S et al. Flow cytimetric analysis of intracellular chemokines in chondrocytes in vivo: costitutive expression and enhancement in osteoarthritis and rheumatoid arthritis. FEBS Lett 1999; 455:238–242.PubMedGoogle Scholar
  89. 89.
    Pulsatelli L, Dolzani P, Piacentini A et al. Chemokine production by human chondrocytes. J Rheumatol 1999; 26:1991–2000.Google Scholar
  90. 90.
    McKee CM, Penno MB, Cowman M et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar machropages: The role of HA size and CD44. J Clin Invest 1996; 98:2403–2413.PubMedGoogle Scholar
  91. 91.
    Beck-Simmer B, Oertli B, Pasch T et al. Hyaluronan induces monocyte chemoattractant protein-1 (MCP-1) expression in renal tubular epithelial cells. J Am Soc Nephrol 1998; 9:2283–2290.Google Scholar
  92. 92.
    Hsu YH, Hsieh MS, Liang YC et al. Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation. J Cell Biochem 2004; 93:929–939.PubMedGoogle Scholar
  93. 93.
    Kanbe K, Takagishi K, Chen Q. Stimulation of matrix metalloproteinase 3 release from human chondrocytes by the interaction of stromal cell-derived factors 1 and CXC chemokine receptor 4. Arthritis Rheum 2002; 46:130–137.PubMedGoogle Scholar
  94. 94.
    Borzì RM, Mazzetti I, Magagnoli G et al. Growth-related oncogene alpha induction of apoptosis in osteoarthritis chondrocytes. Arthritis Rheum 2002; 46:3201–3211.PubMedGoogle Scholar
  95. 95.
    Haringman JJ, Ludikuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 2004; 63:1186–1194.PubMedGoogle Scholar
  96. 96.
    Silvestri T, Meliconi R, Pulsatelli L et al. Down modulation of chemokine receptor cartilage expression in inflammatory arthritis. Rheumatology 2000; 42:14–18.Google Scholar
  97. 97.
    Borzì RM, Mazzetti I, Cattini L et al. Human chondrocytes express functional chemokine receptors and release matrix degrading enzymes in response to C-X-C and C-C chemokines. Arthritis Rheum 2000; 43:1734–1741.PubMedGoogle Scholar
  98. 98.
    Lisignoli G, Toneguzzi S, Pozzi C et al. Proinflammaotry cytokine and chemokine production and expression by human osteoblasts isolated from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1999; 26:791–799.PubMedGoogle Scholar
  99. 99.
    Lisignoli G, Toneguzzi S, Pozzi C et al. Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA, and rheumatoid arthritis (RA) patients. Clin Exp Immunol 1999; 116:371–378.PubMedGoogle Scholar
  100. 100.
    Lisignoli G, Toneguzzi S, Grassi F et al. Different chemokines are expressed in human arthritis bone biopsies: IFN-γ and IL-6 differently modulate IL-8, MCP-1 and RANTES production by arthritic osteoblasts. Cytokine 2002; 20:231–238.PubMedGoogle Scholar
  101. 101.
    Grassi F, Cristino S, Toneguzzi S et al. CXCL12 chemokine upregulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 2004; 199:244–251.PubMedGoogle Scholar
  102. 102.
    Ravaglia G, Forti P, Maioli F et al. Incidence and etiology of dementia in a large elderly Italian population. Neurology 2005; 64:1525–1530.PubMedGoogle Scholar
  103. 103.
    Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol 2005; 37:289–305.PubMedGoogle Scholar
  104. 104.
    Akiyama H, Barger S, Barnim S et al. Inflammation and Alzheimer’s disease. Neurobiol Ageing 2000; 21:383–421.Google Scholar
  105. 105.
    Blasko I, Stampfer-Kountchev M, Robatscher P et al. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell 2004; 3:169–176.PubMedGoogle Scholar
  106. 106.
    Rogers J, Lue LF. Microglial chemotaxis, activation and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer’s disease. Neurochem Int 2001; 39:333–340.PubMedGoogle Scholar
  107. 107.
    Lue LF, Brigham EF, Yang LB et al. Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia 2001; 35:72–79.PubMedGoogle Scholar
  108. 108.
    Franciosi S, Choi HB, Su K et al. IL-8 enhancement of amyloid-beta (Abeta 1–42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J Neuroimmunol 2005; 159:66–74.PubMedGoogle Scholar
  109. 109.
    Fiala M, Zhang L, Gan X et al. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 1998; 4:480–489.PubMedGoogle Scholar
  110. 110.
    Smits HA, Rijsmus A, van Loon JH et al. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol. 2002; 127:160–168.PubMedGoogle Scholar
  111. 111.
    McGeer EG, McGeer PL. Inflammatory processes in Alzheimer’s disease. Prog Neuo-Psychopharmacol Biol PsY 2003; 27:741–749.Google Scholar
  112. 112.
    Ishizuka K, Kimura T, Igatayi R et al. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin Neurosci 1997; 1:135–138.Google Scholar
  113. 113.
    Savchenko VL, McKanna JA, Nikonenko IR et al. Microglia and astrocytes in the adult rat brain: comparative immunocytochemical analysis demonstrates the efficacy of lipocortin 1 immunoreactivity. Neuroscience 2000; 96:195–203.PubMedGoogle Scholar
  114. 114.
    Benzing WC, Wujek JR, Ward EK et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 1999; 20:581–589.PubMedGoogle Scholar
  115. 115.
    Kurt MA, Davies DC, Kidd M. B-amyloid immunoreactivity in astrocytes in Alzheiner’s disease brain biopsies: an electron microscope study. Exp Neurol 1999; 158:221–228.PubMedGoogle Scholar
  116. 116.
    Little AR, Benkovic SA, Miller DB et al. Chemically induced neuronal damage and gliosis: enhanced expression of the pro-inflammatory chemokine, monocyte chemoattractant protein (MCP-1), without a corresponding increase in proinflammatory cytokines. Neuroscience 2002; 115:307–320.PubMedGoogle Scholar
  117. 117.
    Galimberti D, Fenoglio C, Lovati C et al. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease. Neurobiol Aging 2006; 27:262–269.PubMedGoogle Scholar
  118. 118.
    Galimberti D, Schoonenboom N, Scheltens P et al. Intrathecal chemokine syntesis in mild cognitive inpairment and Alzheimer’s disease. Arch Neurol 2006; 63:538–543.PubMedGoogle Scholar
  119. 119.
    Galimberti D, Schoonenboom N, Scarpini E et al. Chemokines in serum and cerebrospinal fluid of Alzheimer’s disease patients. Ann Neurol 2003; 53:547–548.PubMedGoogle Scholar
  120. 120.
    Halks-Miller M, Schroeder ML, Haroutunian V et al. CCR1 is an early and specific marker of Alzheimer’s. Ann Neurol 2003; 54:638–646.PubMedGoogle Scholar
  121. 121.
    Xia MQ, Qin SX, Wu LJ et al. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligand in normal and Alzheimer’s disease brains. Am J Pathol 1998; 153:31–37.PubMedGoogle Scholar
  122. 122.
    Hesselgesser J, Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol 1999; 5:13–26.PubMedGoogle Scholar
  123. 123.
    Huerta C, Alverez V, Mata IF et al. Chemokines (RANTES and MCP-1) and chemokine receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer’s and Parkinson’s disease. Neurosci Lett 2004; 370:151–154.PubMedGoogle Scholar
  124. 124.
    Combarros O, Infante J, Liorca J et al. No evidence for association of the monocyte chemoattractant protein-1 (−2518) gene polymorphism and Alzheimer’s disease. Neurosci Lett 2004; 360:25–28.PubMedGoogle Scholar
  125. 125.
    Galimberti D, Fenoglio C, Lovati C et al. CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer’s disease. J Neurol Sci. 2004; 225:79–83.PubMedGoogle Scholar
  126. 126.
    Pola R, Flex A, Gaetani E et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer’s disease in Italians. Exp Gerontol. 2004; 39:1249–1252.PubMedGoogle Scholar
  127. 127.
    Fenoglio C, Galimberti D, Lovati C et al. MCP-1 in Alzheimer’s disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 2004; 25:1169–1173.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  • Erminia Mariani
    • 2
  • Adriana Rita Mariani
    • 1
  • Andrea Facchini
    • 1
  1. 1.Dipartimento di Medicina Interna e GastroenterologiaUniversity of BolognaBolognaItaly
  2. 2.Laboratorio di Immunologia e Genetica, Istituto di Ricerca Codivilla-PuttiIORBolognaItaly

Personalised recommendations